Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Navann Ty
EB
Navann Ty
Exane BNP Paribas
Wall Street Analyst
★★☆☆☆
#2249
on 13Foresight · ranked by our own returns
35%
Success Rate
-12.0%
Average Return
6 of 17 calls profitable · -23.2% vs benchmark
📈 Across the calls we could measure, roughly 35% of Navann Ty's ratings turned a profit when each position was held for 1 year — averaging -12.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

3 Buy 5 Hold 0 Sell
Navann's Stock Coverage 17 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
OGN
Organon
 Apr 28, 2026 HOLD Sell
+10.6% avg upside
9 analysts
$14.00
4.30% Upside
 +0.9%
MDLN
Medline
 Jan 12, 2026 HOLD Strong Buy
+42.9% avg upside
26 analysts
$38.00
5.65% Upside
 -15.9%
NTRA
Natera
 Oct 27, 2025 HOLD Strong Buy
+7.6% avg upside
26 analysts
$172.00
25.67% Downside
 +17.8%
GEHC
GE Healthcare Technologies Inc
 Sep 10, 2025 BUY Strong Buy
+36.1% avg upside
20 analysts
$92.00
49.36% Upside
 -14.1%
PAHC
Phibro Animal Health
 Sep 04, 2025 HOLD Hold
+17.0% avg upside
10 analysts
$37.00
16.14% Upside
 -16.6%
COO
Cooper Co
 Jul 22, 2025 BUY Buy
+102.5% avg upside
21 analysts
$92.00
39.62% Upside
 -7.8%
KVUE
Kenvue, Inc.
 May 30, 2023 HOLD Hold
+9.6% avg upside
17 analysts
$28.00
54.46% Upside
 -23.2%
SKIN
Beauty Health
 Mar 20, 2023 HOLD Hold
+408.7% avg upside
11 analysts
 — -61.8%
EOLS
Evolus
 Dec 08, 2022 BUY Strong Buy
+116.3% avg upside
9 analysts
$13.00
96.14% Upside
 +28.7%
ABBV
AbbVie
 Dec 08, 2022 HOLD Buy
+2.8% avg upside
43 analysts
$169.00
22.00% Downside
 -6.4%
ALKS
Alkermes
 Mar 22, 2022 HOLD Strong Buy
-17.5% avg upside
34 analysts
$26.00
42.25% Downside
 -1.0%
VTRS
Viatris
 Mar 10, 2022 HOLD Buy
+48.2% avg upside
21 analysts
$11.00
28.38% Downside
 +3.3%
ZTS
Zoetis
 Mar 09, 2022 HOLD Buy
+71.4% avg upside
22 analysts
$208.00
164.18% Upside
 -10.9%
JAZZ
Jazz Pharmaceuticals
 Oct 05, 2021 BUY Strong Buy
-1.8% avg upside
35 analysts
$200.00
10.94% Downside
 +6.5%
ELAN
Elanco Animal Health
 May 17, 2021 BUY Strong Buy
+24.1% avg upside
18 analysts
$42.00
73.32% Upside
 -30.9%
TSE:BHC
Bausch Health Companies
 Mar 02, 2021 BUY Buy
+783.6% avg upside
29 analysts
$51.79
668.45% Upside
 ·
TEVA
Teva Pharmaceutical
 Apr 24, 2020 HOLD Buy
-6.8% avg upside
39 analysts
$10.00
68.19% Downside
 +0.2%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Navann Ty — Frequently Asked Questions
How accurate are Navann Ty's stock ratings?
Based on the calls 13Foresight could measure, about 35% of Navann's ratings were profitable over a one-year hold, with an average return of -12.0% per rating, or -23.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Navann ranked on 13Foresight?
Navann Ty is currently ranked #2249 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Navann cover?
Navann most recently has ratings on OGN, MDLN, NTRA, GEHC, PAHC, COO, KVUE, SKIN, EOLS, ABBV, ALKS, VTRS and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.